To assess the prevalence of neuropsychiatric symptoms (NPS) in mild-to-moderate Alzheimer disease (AD) and their association with caregiver burden.
Methods:
Secondary analyses of baseline data from the Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD) (N=613). Neuropsychiatric Inventory were used to measure severity of NPS and caregiver activity survey to measure caregiver burden.
Results:
A total of 87% of patients displayed at least 1 NPS; 70% displayed clinically meaningful NPS. The most common symptoms were apathy (47%), irritability (44%), agitation (42%), and depression (40%). Those with moderate AD had more severe NPS than those with mild AD (P = .03). Neuropsychiatric symptoms were significantly associated with caregiver time after adjusting for age, education, cognitive function, and comorbidity (P-value < .0001) with every point increase in NPS associated with a 10-minute increase in caregiver time.
Conclusion:
Neuropsychiatric symptoms were prevalent in both mild and moderate AD, even in patients receiving treatment with an acetylcholinesterase inhibitors, and were more severe in moderate AD and associated with greater caregiver time.
KatzmanR. The prevalence and malignancy of Alzheimer disease: a major killer. Arch Neurol. 1976;33(4):217–218.
2.
HebertLEScherrPABieniasJL. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–1122.
3.
ChenPGanguliMMulsantBHDeKoskyST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry. 1999;56(3):261–266.
4.
TractenbergREWeinerMFPattersonMB. Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer’s disease. J Geriatr Psychiatry Neurol. 2003;16(2):94–99.
5.
GedaYESchneiderLSGitlinLN. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–608.
6.
LyketsosCGCarrilloMCRyanJM. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–539.
7.
CummingsJLMegaMGrayK. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994:44;2308–2314.
8.
LyketsosCGSteinbergMTschanzJT. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–714.
9.
GedaYERobertsROKnopmanDS. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65(10):1193–1198.
10.
SteffensDCMaytanMHelmsMJPlassmanBL. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimers Dis Other Demen. 2005;20(6):367–373.
11.
OkuraTPlassmanBLSteffensDC. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc. 2010;58(2):330–337.
12.
ZuidemaSKoopmansRVerheyF. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007;20(1):41–49.
13.
SteinbergMShaoHZandiP. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–177.
14.
BenoitMRobertPHStacciniP. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer’s disease. The REAL.FR Study. J Nutr Health Aging. 2005;9(2):95–99.
15.
AllegriRFSarasolaDSerranoCM. Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2006;2(1):105–110.
16.
PetersMESchwartzSHanD. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460–465.
17.
TootSSwinsonTDevineM. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr. 2017;29(2):195–208.
18.
OkuraTPlassmanBLSteffensDC. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–481.
19.
OkuraTLangaKM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis Assoc Disord. 2011;25(2):116–121.
20.
BergerGBernhardtTWeimerE. Longitudinal study on the relationship between symptomatology of dementia and levels of subjective burden and depression among family caregivers in memory clinic patients. J Geriatric Psychiatry Neurology. 2005;18(3):119–128.
21.
TrinhNHHoblynJMohantySYaffeK. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210–216.
22.
HuangYJLinCHLaneHYTsaiGE. NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s disease. Curr Neuropharmacol. 2012;10(3):272–285.
23.
Rojas-FernandezCMikhailMBrownSG. Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice. Ann Pharmacother. 2014;48(4):438–446.
24.
RosenblattASamusQMOnyikeCU, Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. Int J Geriatr Psychiatry. 2008;23(2):178–184.
25.
MaxwellCJVuMHoganDB. Patterns and determinants of dementia pharmacotherapy in a population-based cohort of home care clients. Drugs Aging. 2013;30(7):569–585
26.
FereshtehnejadSMJohnellKEriksdotterM. Anti-dementia drugs and co-medication among patients with Alzheimer’s disease. Drugs Aging. 2014;31(3):215–224.
27.
DyskenMWGuarinoPDVertreesJE. Vitamin E and memantine in Alzheimer’s disease: clinical trial methods and baseline data. Alzheimers Dement. 2014;10(1):36–44.
28.
McKhannGDrachmanDDFolsteinM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force in Alzheimer’s Disease. Neurology. 1984;34(7):939–944.
29.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
30.
DyskenMWSanoMAsthanaS, Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA Cooperative randomized trial. JAMA. 2014;311(1):33–44
31.
GalaskoDBennetDSanoM. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33–S39.
32.
MohsRCRosenWGDavisKL. The Alzheimer’s disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19(3):448–450.
33.
RosenWGMohsRCDavisKL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356–1364.
34.
SternYAlbertSMSanoM. Assessing patient dependence in Alzheimer’s disease. J Gerontol. 1994;49(5):M216–M222.
35.
DavisKMarinDKaneR. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12(10):978–988.
36.
Lyketsos 2002 LyketsosCGLopezO. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–1483.
National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. Review of NICE technology appraisal guidance 111. NICE technology appraisal guidance 217. London: NICE, 2011.
39.
SAS. SAS Institute. SAS/GIS 9.2: Spatial Data and Procedure Guide. Cary, NC: SAS Institute, Inc; 2009.
40.
AaltenPde VugtMEJaspersN. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005:20(6):523–530.
41.
RyuSHKatonaCRiveBLivingstonG. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry. 2005;13(11):976–983.
42.
SelbækGEngedalKBerghS. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. J Am Med Dir Assoc. 2013;14(3):161–169.
43.
HowardRJJuszczakEBallardCG. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357(14):1382–1392.
44.
JostBCGrossbergGT. The natural history of Alzheimer’s disease: a brain bank study. J Am Geriatr Soc. 1995;43(11):1248–55
45.
RopackiSAJesteDV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11):2022–2030
46.
Van DamDVermeirenYDekkerAD. Neuropsychiatric disturbances in Alzheimer’s disease: what have we learned from neuropathological studies?Curr Alzheimer Res. 2016;13(10):1145–1164.
47.
IsmailZSmithEEGedaY. ISTAART Neuropsychiatric Symptoms Professional Interest Area. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202.
48.
RosenbergPBNowrangiMALyketsosCG. Neuropsychiatric symptoms in Alzheimer’s disease: what might be associated brain circuits?Mol Aspects Med. 2015;43–44:25–37.
49.
MohamedSRosenheckRLyketsosCGSchneiderLS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010;18(10):917–927
50.
SheikhFIsmailZMortbyME. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. International Psychogeriatrics. 2017;30(2):1–12
51.
JutkowitzEKuntzKMDowdBGauglerJEMacLehoseRFKaneRL. Effects of cognition, function, and behavioral and psychological symptoms on out-of-pocket medical and nursing home expenditures and time spent caregiving for persons with dementia. Alzheimers Dement. 2017;13(7):801–809.
52.
FeastAMoniz-CookEStonerCCharlesworthGOrrellM.A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being. Int Psychogeriatr. 2016;28(11):1761–1774
53.
CostaNWübkerAMauléonACosts of Care of Agitation Associated With Dementia in 8 European Countries: Results From the RightTimePlaceCare Study. J Am Med Dir Assoc. 2018;19(1):95.e1–e95.e10.
54.
KalesHCGitlinLNLyketsosCG. Management of the neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–769
55.
ReusVIFochtmannLJEylerAE. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–546
56.
KalesHCGitlinLNLyketsosCG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350: h369 doi:10.1136/bmj.h369
57.
KarelMJTeriLMcConnellE. Effectiveness of expanded implementation of STARVA for managing dementia-related behaviors among veterans. Gerontologist. 2016;56(1):126–134.
58.
AbrahaIRimlandJMTrottaFM. Systematic review of systematic reviews of nonpharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open. 2017;7:e012759. doi:10.1136
59.
ScalesKZimmermanSMillerSJ. Evidence-based nonpharmacological practices to address behavioral and psychological symptoms of dementia. Gerontologist. 2018;58(suppl_1): S88–S102.
60.
AustromMGBoustaniMLaMantiaMA. Ongoing medical management to maximize health and well-being for persons living with dementia. Gerontologist. 2018;18: 58(suppl_1): S48–S57.
